Bristol-Myers Squibb urged shareholders on Wednesday to support its planned $74 billion takeover of Celgene Corp, as it faces opposition from two large investors to what could be the largest pharmaceutical deal ever.
Source:: Reuters – Business News
Newswire
- [ November 5, 2025 ] Worksport (NASDAQ: WKSP) Releases Final COR System Specifications & Pricing Newsmakers
- [ November 3, 2025 ] Worksport (NASDAQ: WKSP) to Showcase SOLIS™ and COR™ at SEMA 2025, Expanding Global Distribution Opportunities Newsmakers
- [ October 27, 2025 ] Advent Technologies (NASDAQ: ADN) Commissions Arxicon as Master Planner for RHyno Project Newsmakers
- [ October 27, 2025 ] Hoth Therapeutics (NASDAQ: HOTH) Launches VA-Backed Study of Novel GDNF Weight Loss Therapy Targeting Obesity and Fatty Liver Disease Newsmakers
- [ October 23, 2025 ] Worksport (NASDAQ: WKSP) Announces New HD3 Heavy-Duty Tonneau Cover Now in Production Newsmakers
- [ October 21, 2025 ] Hoth Therapeutics (NASDAQ: HOTH) Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers Newsmakers
- [ October 16, 2025 ] Worksport (NASDAQ: WKSP) Reports Record Q3 Revenue Growth and 2,300 Basis-Point Margin Expansion Ahead of Three Clean-Energy Product Launches Uncategorized
- [ October 15, 2025 ] Worksport Ltd. (NASDAQ: WKSP) Successfully Closes $10 Million Regulation A Funding; Launch-Ready and Fully Capitalized for Early 2026 Cash Flow Positivity Newsmakers
- [ October 9, 2025 ] Hoth Therapeutics (NASDAQ: HOTH) Expands Artificial Intelligence Initiative, Selects NVIDIA AI Enterprise Platform Newsmakers
- [ October 9, 2025 ] Hoth Therapeutics (NASDAQ: HOTH) CEO Robb Knie to Present at BIO-Europe in Vienna, Austria November 3-5, 2025 Newsmakers
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.